Literature DB >> 27263741

The changes in complete blood count in thyroid cancer patients treated with radioactive iodine ablation therapy.

Bircan Sönmez1, İsmail Doğan, Canan Yavruoğlu, Gamze Can, Mehmet Sönmez.   

Abstract

OBJECTIVE: The aim of this study was to evaluate the effect of radioactive iodine (RAI) ablation therapy on the complete blood count (CBC) in thyroid cancer patients.
METHODS: One hundred sixty four patients undergoing RAI ablation therapy after total thyroidectomy were included. CBC results were available from the patients' medical records at the time of ablation and at the 1st, 6th, and 12th months after RAI therapy.
RESULTS: Hemoglobin (Hb), white blood cell (WBC) and platelet (Plt) values were significantly lower than baseline at 1 month after treatment (p <0.0001). Hb and WBC values were increased at the 6th month and at the 1st year. Plt values increased at the 6th month but had decreased again at the 1st year. The values were usually in normal ranges except in the patients with low pretreatment Hb and WBC values.
CONCLUSION: RAI ablation therapy in thyroid cancer patients is a safe treatment modality without any serious or persistent hematological side effects.

Entities:  

Year:  2010        PMID: 27263741     DOI: 10.5152/tjh.2010.49

Source DB:  PubMed          Journal:  Turk J Haematol        ISSN: 1300-7777            Impact factor:   1.831


  3 in total

1.  Blood cells in thyroid cancer patients: a possible influence of apoptosis.

Authors:  Olgica B Vrndic; Predrag M Djurdjevic; Danijela D Jovanovic; Ljiljana C Mijatovic Teodorovic; Irena R Kostic; Ilija D Jeftic; Snezana T Zivancevic Simonovic
Journal:  Open Med (Wars)       Date:  2016-04-18

Review 2.  Radioactive Iodine Therapy and Glucose Tolerance.

Authors:  Roghaieh Samadi; Babak Shafiei; Fereidoun Azizi; Asghar Ghasemi
Journal:  Cell J       Date:  2017-02-22       Impact factor: 2.479

3.  Assessment of Long-Term Hematologic Effects in Differentiated Thyroid Cancer Patients Treated with Radioactive Iodine

Authors:  Bircan Sönmez; Özlen Bektaş; Nergiz Erkut; Mehmet Sönmez
Journal:  Turk J Haematol       Date:  2021-03-22       Impact factor: 1.831

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.